Racial Disparities in Systemic Sclerosis: Short‐ and Long‐Term Outcomes Among African American Participants of SLS I and II

To evaluate short‐ and long‐term outcomes of African American (AA) participants of Scleroderma Lung Studies (SLS) I and II.

[1]  K. Bandeen-Roche,et al.  Appendix 1 , 2019, European Journal of Human Genetics.

[2]  V. Steen,et al.  Increased Morbidity and Mortality of Scleroderma in African Americans Compared to Non–African Americans , 2019, Arthritis care & research.

[3]  G. Raghu,et al.  Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. , 2019, The New England journal of medicine.

[4]  R. Elashoff,et al.  Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts , 2018, Annals of the rheumatic diseases.

[5]  M. Roth,et al.  Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II , 2018, Annals of the American Thoracic Society.

[6]  Ami A. Shah,et al.  Clinical and serological features of systemic sclerosis in a multicenter African American cohort , 2017, Medicine.

[7]  Gang Li,et al.  Joint Modeling of Longitudinal and Time-to-Event Data , 2016 .

[8]  R. Elashoff,et al.  Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-related Interstitial Lung Disease: Scleroderma Lung Study II (SLS-II), a double-blind, parallel group, randomised controlled trial , 2016, The Lancet. Respiratory medicine.

[9]  A. Grey,et al.  Reporting of Limitations of Observational Research. , 2015, JAMA internal medicine.

[10]  Ami A. Shah,et al.  Race and Association With Disease Manifestations and Mortality in Scleroderma , 2013, Medicine.

[11]  R. Domsic,et al.  A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis. , 2012, Arthritis and rheumatism.

[12]  M. Mayes,et al.  Gender and ethnicity differences in patients with diffuse systemic sclerosis--analysis from three large randomized clinical trials. , 2011, Rheumatology.

[13]  M S Brown,et al.  A computer-aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients. , 2010, Clinical and experimental rheumatology.

[14]  R. Elashoff,et al.  Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. , 2009, Chest.

[15]  Charlie Strange,et al.  Cyclophosphamide versus placebo in scleroderma lung disease. , 2006, The New England journal of medicine.

[16]  Brenda W Gillespie,et al.  Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. , 2003, Arthritis and rheumatism.

[17]  J. Fifield,et al.  Characteristics of rheumatoid arthritis patients: who participates in long-term research and who drops out? , 2000, Arthritis care and research : the official journal of the Arthritis Health Professions Association.

[18]  M. Mayes,et al.  Racial differences in scleroderma among women in Michigan. , 1997, Arthritis and rheumatism.

[19]  T. Medsger,et al.  Incidence of systemic sclerosis in Allegheny County, Pennsylvania. A twenty-year study of hospital-diagnosed cases, 1963-1982. , 1997, Arthritis and rheumatism.

[20]  David R. Williams.  Race/Ethnicity and Socioeconomic Status: Measurement and Methodological Issues , 1996, International journal of health services : planning, administration, evaluation.

[21]  Saburō Shiroyama.  In Los Angeles , 1989, Made in Japan and other Japanese “Business Novels”.

[22]  P. Clayton,et al.  Lung volumes in healthy nonsmoking adults. , 1982, Bulletin europeen de physiopathologie respiratoire.

[23]  J L Hankinson,et al.  Spirometric reference values from a sample of the general U.S. population. , 1999, American journal of respiratory and critical care medicine.